B7-H4 Rat anti-Mouse, Clone: 297219, Invitrogen
Rat Monoclonal Antibody
Manufacturer: Invitrogen MA524006
In Western blots, no cross-reactivity with recombit mouse (rm) B7-1, rmB7-2, rmB7-H1, rmB7-H2, rmB7-H3, recombit human (rh) B7-H3b, rhB7-H4, or rmPD-L2 is observed. Reconstitute at 0.5 mg/mL in sterile PBS.B7-H4 (B7x, VTCN1) a costimulatory protein which is reported to function as a negative regulator of T-cell mediated immunity. Although B7-H4 binds an unknown receptor, it is thought to deliver an inhibitory signal to T-cells preventing their proliferation, cell cycle progression and interleukin-2 production. B7-H4 deficient mice are only minimally affected; suggesting B7-H4 is important in the fine tuning of the T-cell mediated immune response. B7-H4 is expressed on activated T-cells, B-cells, monocytes and dendritic cells. Aberrant expression has been associated with cancers of the lung, breast and ovary in humans. B7-H4 is expressed primarily on the membrane of lymphoid cells, and as an immunoinhibitory protein that interacts with receptors on the surface of T lymphocytes, it is involved in mediating cellular and humoral immune responses. Overexpression of B7-H4 is associated with certain maligcies, including ovarian and breast cancer, which may be a mechanism by which tumor cells suppress T cell immunity and facilitate tumor progression. Further, VTCN1 may be a useful biomarker for the early detection of ovarian cancer and Renal Cell Carcinoma (RCC).
|PBS with 5% trehalose and No Preservative|
|VTCN1, V-set domain containing T cell activation inhibitor 1, T cell costimulatory molecule B7x, B7-H4, B7H4, B7S1, B7X|
|-20° C, Avoid Freeze/Thaw Cycles|
|Flow Cytometry, Western Blot|
|Mouse myeloma cell line NS0-derived recombit mouse B7-H4 Phe29-Pro258|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok